Regeneron Pharmaceuticals, Inc. $REGN Position Lessened by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,442 shares of the biopharmaceutical company’s stock after selling 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Regeneron Pharmaceuticals were worth $18,094,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Brighton Jones LLC raised its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $3,183,000. Gabelli Funds LLC raised its stake in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $614.78 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market cap of $64.99 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 1.36 and a beta of 0.25. The business’s fifty day moving average is $719.15 and its 200-day moving average is $744.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm posted $8.22 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Truist Financial cut their target price on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $792.65.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron said the World Health Organization recommended its Ebola antibody treatment, Inmazeb, for investigational use in response to the current Bundibugyo ebolavirus outbreak, highlighting continued relevance for an approved infectious-disease asset. Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
• Positive Sentiment: The company expanded its clinical pipeline with a new Phase 2 trial for REGN13335 in pulmonary hypertension, adding another potential growth driver. Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335
• Positive Sentiment: Regeneron also announced a new Phase 1 CAR T study in advanced prostate cancer, reinforcing its push into oncology and cell therapy. Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
• Neutral Sentiment: Brokerage coverage remains supportive, with Regeneron receiving an average “Moderate Buy” recommendation from analysts, which can help cushion sentiment but is not a major catalyst. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages
• Neutral Sentiment: Recent articles about REGN trading lower since its last earnings report mainly reflect post-earnings drift and analyst estimate checks rather than a fresh company-specific setback. Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: A law firm investor alert announcing an investigation into claims on behalf of Regeneron shareholders may have added legal overhang and contributed to negative sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.